• Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
  
• Gene deletion; HGNC; HGNC:9588; PTEN; Zygosity=Heterozygous (PubMed=22194965).
  
• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (PubMed=22194965).
  

PubMed=21107323; DOI=10.1038/nature09626; PMCID=PMC3143360
Ramin Nazarian, Hu-Bing Shi, Qi Wang, Xiang-Ju Kong, Richard C. Koya, Hane Lee, Zu-Gen Chen, Mi-Kyung Lee, Narsis Attar, Hooman Sazegar, Thinle Chodon ...Show all 16 authors... , Stanley F. Nelson, Grant A. McArthur, Jeffrey Alan Sosman, Antoni Ribas, Roger S. Lo; Show fewer authors
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nature 468:973-977(2010)

PubMed=22194965; DOI=10.1371/journal.pone.0028973; PMCID=PMC3237573
Mohammad Atefi, Erika Maria von Euw, Narsis Attar, Charles Ng, Connie Chu, De-Liang Guo, Ramin Nazarian, Bartosz Chmielowski, John A. Glaspy, Begonya Comin-Anduix, Paul Salomon Mischel ...Show all 13 authors... , Roger S. Lo, Antoni Ribas; Show fewer authors
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.
PLoS ONE 6:e28973.1-e28973.12(2011)

PubMed=24735930; DOI=10.1186/1476-4598-13-83; PMCID=PMC4021505
Amanda Lassen, Mohammad Atefi, Lidia Robert, Deborah Jean Lee Wong, Michael Cerniglia, Begonya Comin-Anduix, Antoni Ribas;
Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.
Mol. Cancer 13:83.1-83.14(2014)